{"id":"NCT01224171","sponsor":"Millennium Pharmaceuticals, Inc.","briefTitle":"Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease","officialTitle":"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2012-02","completion":"2012-04","firstPosted":"2010-10-19","resultsPosted":"2014-07-21","lastUpdate":"2014-07-21"},"enrollment":416,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"vedolizumab","otherNames":["Entyvio","MLN0002","MLN02","LDP-02"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vedolizumab","type":"EXPERIMENTAL"}],"summary":"This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.","primaryOutcome":{"measure":"Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFÎ±) Antagonist Failure Subpopulation","timeFrame":"Week 6","effectByArm":[{"arm":"Placebo","deltaMin":12.1,"sd":null},{"arm":"Vedolizumab","deltaMin":15.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4332"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":41,"countries":["United States","Canada"]},"refs":{"pmids":["30615117","30203005","29857145","26893500","25996351","24859203"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":207},"commonTop":["Headache","Pyrexia","Nausea"]}}